- Hi-Tech Pharmacal receives market exclusivity for generic Neurontin
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Moving PSE to Rx-only in Mo. lacks fiscal sense
- FDA, parent agency HHS divided over emergency contraceptive prescription status
- NeurogesX seeks expanded approval for Qutenza
SAM MATEO, Calif. — A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.
NeurogesX said Thursday that the FDA Anesthetic and Analgesic Drug Products Advisory Committee would meet on Feb. 9, 2012, to review the patch drug Qutenza (capsaicin) as a treatment for pain associated with HIV-associated peripheral neuropathy, or HIV-PN.
The drug currently is approved for treating pain associated with postherpetic neuralgia.
NeurogesX filed with the FDA for approval of the drug last month, and the agency expects to decide whether to approve it in early March. While the FDA usually follows the recommendations of advisory committees, it is not bound by them.